Arctium lappa L. (Asteraceae family), commonly greater burdock, is a biennial species found across most of tEurope, Asia and also America. The root part, Bardanae radix, is used as a herbal medicine, but is also used as a vegetable in Eastern Asian regions (similar to potatoes) due to its nutritional value , the high content of carbohydrates (69%) including inulin (27-50%) and mucilage added to fats, proteins and numerous vitamins (B1, B2, B3, B5, B6, B9, C, E and K) and minerals (Ca, Fe, Mg, Mn, P, K, Na and Zn)  respectively.
Concerning the basis of its medicinal use, data indicate that Bardanae radix is rich in caffeoylquinic acid isomers [1, 3], with dicaffeoylquinic acid derivatives being quantified at 75.4% and 1,5-di-O-caffeoyl-4-O-maloylquinic acid representing 44% of the total isomers , but that the content also comprisesnumerous other secondary metabolites such as tannin-iron complexes, various polyacetylenes and sulphuric actylene compounds, essential oils, guainolides and bitter compounds, lignans (e.g., arctigenin, arctiin,) and sterols (e.g., sitosterol, stigmasterol) . Studies regarding the metabolic profile of the compounds of burdock plant pieces indicated caffeoylquinic acid derivates and luteolin and quercetin rhamnosides occur in the root part, caffeoylquinic acid and quercetin, quercitrin and luteolin derivates in the leaves, whereas cynarin and chlorogenic acid are dominant in the seeds .
Based on this valuable phytochemical content, Bardanae radix represents an important ingredient for traditional medicine practitioners, and has also achieved international recognition for its numerous healthy effects ; Romanian folk medicine also considers a bardanae radix hot water extract (decoction type) as an effective expectorant, anti-tussive, emollient, diuretic and anti-inflammatory remedy thus being recommended for different lung, digestive, renal and skin ailments . Proving these, studies have reported burdock products and corresponding separate extracts or specific compounds (especially lignans such as arctiin and arctigenin, and polyphenols compounds) having antioxidant, anti-inflammatory, antitumor, antibacterial and antiviral activities , as well as hepatoprotective , antiurolithiasic  and skin improving [1, 9] effects, with some clinical studies also proving their effectiveness in knee osteoarthritis  and for dental infectious conditions [11, 12]; burdock root and fruits are also reported to have antidiabetic activity [1, 4], with their beneficial effects being attributed to the copresence of sitosterol, inulin and lignans. Furthermore, the combination arctigenin - polyphenols have shown the capacity to block tumor cell growth and metastasis . Additionally, arctiin, caffeic and chlorogenic acid mixtures have proven significant anti-mutagenic effects and a positive correlation with polyphenolic content . Concerning the biochemical pathway involved, studies on arctigenin tested on MH60 cells indicated the stimulation of apoptosis (IC50 = 1.0 μM) as being the most probable mechanism , while the capacity of polyphenols to protect the cells against radical oxygen species (ROS) injuries and to stimulate immune processes  are believed to effectively contribute to the antitumor effect of burdock products.
The leaves of Arctium lappa L. have been recognized as havingsome antimicrobial properties against some bacterial strains found in endodontic infections such as Bacillus subtilis, Lactobacillus acidophilus and Pseudomonas aeruginosa, as well as on Candida albicans, Escherichia coli, Staphylococcus aureus and Micrococcus luteus . Furthermore, the efficacy of burdock leaf derived products against influenza A virus (A/NWS/33, H1N1) (IFV) , herpesvirus (HSV-1, HSV-2), adenovirus (ADV-3, ADV-11), and human immunodeficiency virus (HIV-1)  has also been proven.
Thus, in the current upward trend of using plant derived products as natural medicines, while at the same time increasing bacterial resistance to antibiotics of all classes, based on these data, but also on our previous results [19, 20] demonstrating the antimicrobial effects of some whole and selective extracts from medicinal plants growing in Romania, this study was aimed to evaluate any potential interaction of Arctii folium extracts with typical antibiotics. The results of the study are very useful to avoid situations of incompatibility with such antibiotics, but also as the starting point for developing new natural synergistic products able to restore antimicrobic susceptibility.
2 Experimental Procedure
2.1.1 Plant material description
Leaves from burdock (Arctii folium) were harvested in June and September from the Romanian Carpathians, Sinaia region (1,000 m altitude). Taxonomic identification was carried out by the botanist’s team of the National Institute of Chemical-Pharmaceutical R&D (ICCF Bucharest), Romania. The burdock leaves were shade dried and ground to a medium-size plant powder; voucher specimens (ALam7.1, Alam7.2) are deposited in the ICCF Plant Material Storing Room.
2.1.2 Vegetal extracts preparation
Fifty (50) g of leaf powder (Arctii folium) were heat-assisted extracted (twice) with 500 mL of 70% (v/v) ethanol. The total extract obtained was filtered through a (medium) paper filter, resulting in 650 mL ethanol extract (E7). Two hundred and fifty (250) mL of (E7) ethanol extract was concentrated at low pressure at sicc product then passed into 20% (v/v) propylene glycol (20% PG) solution so as to ensure a final concentration of exactly 5 mg total phenols (expressed as gallic acid [GAE] equivalents) per 1 mL extract, further called Arctii folium whole ethanol extract (codified W); the whole ethanol extract (W) was divided into 2 mL Eppendorf tubes and stored at -8 °C until microbiological studies. Another two hundred and fifty (250) mL of (E7) ethanol extract was also concentrated at sicc product then dissolved into 100 mL of distilled water. The resulting aqueous solution was (manually) extracted first with (3 x 100 mL) chloroform and then with (3 x 100 mL) ethyl acetate solvent, 24 hours per each stage. Three selective extracts were obtained: aqueous (AQ), ethyl acetate (EA) and chloroform (CHL) fractions, respectively. The three Arctii folium selective fractions were analyzed as concerning total phenols content (GAE per 1 mL sample) then concentrated at sicc product and (separately) passed into 20% PG as follows: aqueous and ethyl acetate fractions were prepared so as to achieve identical 5 mg GAE / 1 mL samples, while the chloroform fraction (CHL) was passed into 20% PG by means of the whole extract algorithm so as to assure the same amount of non-polar compounds. Similarly, the three selective extracts, AQ, EA and CHL (test extracts) were divided into monodoses and stored at -8 °C until microbiological studies.
2.1.3 Chemicals, reagents and references
Reagents (Folin-Ciocalteau and Natural Product) and solvents (methanol, ethanol, ethyl acetate, formic acid, glacial acetic acid and chloroform) were purchased from Sigma-Aldrich Co, Fluka and Biochemika, as well as quercetin (95%), rutin (min. 95%), quercitrin (>90%), isoquercitrin (>90%), hyperoside (>97%), apigenin (>97%), vitexin-2’’O-rhamnoside (>98%), apigenin 7-O-apiosylglucoside/apiin (>99%), chlorogenic acid (>95%), rosmarinic acid (97%), caffeic acid (>98%) and cynarin (analytical standard) polyphenols compounds – the reference substances (ref.).
2.2 Experimental Design
2.2.1 Qualitative (HP)TLC analysis
2.2.2 Estimation of Total Phenolics Content
2.2.3 Antimicrobial Activity Assay
220.127.116.11 Test organisms
Nine reference bacterial strains (ATCC strains purchased from Thermo Scientific Romania) were used, including four Gram-positive bacteria (Staphylococcus aureus ATCC 6538, Staphylococcus aureus ATCC 25923, Enterococcus faecalis ATCC 29212, and Staphylococcus epidermidis ATCC 12228) and five Gram-negative bacteria (Proteus mirabilis ATCC 29245, Escherichia coli ATCC 35218, E. coli ATCC 11229, E. coli ATCC 8739, and Bacillus cereus ATCC 11778). Nutrient broths (Oxoid CM0001) and Muller-Hinton agar (Oxoid CM0337) culture media were used (prepared from a dehydrated base according with the manufacturer’s recommendations).
18.104.22.168 Test antimicrobials
Six antibiotics (microtablets purchased from Biolab Zrt. Romania) were used: Ampicillin (AM, 10 μg), Gentamicin (CN, 10 μg), Tetracycline (TE, 30 μg), Sulfamethoxazole/Trimethoprim (SXT, 25 μg), Ciprofloxacin (CIP, 5 μg), and Chloramphenicol (C, 30 μg).
22.214.171.124 Inoculum preparation
The microorganisms were stored in freezing conditions and activated by cultivation in Nutrient broth at 37 °C for 24 hours. Bacterial inoculums were prepared from an overnight broth culture in demineralised water in order to obtain a bacterial turbidity equivalent to 0.5 McFarland standards .
126.96.36.199 Minimum inhibitory concentration (MIC) assay
The experiments were accomplished using the reference method for testing the in vitro activity of the antimicrobial agents, ISO 20776-1/2006  and CLSI M07-A9 document . MIC appraisals were carried out using an accurate working scheme (see Table 1S) as follows: four identical Arctii folium dilution series were prepared, corresponding to four test extracts, i.e. the whole ethanol extract/W and the three selective fractions/AQ, EA, CHL, each one precisely quantified as concerning total phenols content (μg GAE / 1 mL sample); the dilution series were fulfilled by incorporation of each vegetal extract into Muller-Hinton Agar (MHA) medium so that the concentration level of the four test extracts (dilution series) ranged in the interval 4 – 1024 μg GAE / mL in case of the polar extracts (W, AQ and EA) and 0.1 – 25.6 μg GAE / mL in case of nonpolar extract (CHL); MHA medium + PG 20% solution (4.1 ml + 0.9 ml) was used as the negative control. After the solidification of the MHA mixed with the tested vegetal extract, the bacterial inoculum (104 cfu/spot) was applied to the surface of the medium and the plates were incubated for 24 hours at 37 °C. The results were interpreted according to literature data  by evaluating the bacterial growth at respective vegetal extract dilution series and concentration of phenols.
188.8.131.52 Synergism assay
The assessment of potential interactions between the four Arctii folium extracts and the six antibiotics (microtablets of accurate concentration) has as scientific basis and further design study model their combination at the MIC/2 concentration level . Thus, the culture medium (MHA) was prepared by incorporating Arctii folium extracts so that the polyphenols have a concentration corresponding to MIC/2. The dried surface of the culture medium was thus inoculated with a bacterial suspension at 1-2x108 UFC / mL and subsequently the antimicrobial micro-tablets were distributed to achieve MIC/2 concentration level as well. The plates were incubated for 24 hours at 37 °C, and then the antimicrobial effect was evaluated by measuring the inhibition area around the microtablets.
For each antimicrobial substance (positive control/C), four combinations were designated: C+Whole extract (C+W), C+Aqueous extract (C+AQ), C+Ethyl acetate fraction (C+EA) and C+ Chloroform fraction (C+CHL).
184.108.40.206 Statistical analysis
Results are expressed as the mean ± SD of three experiments; significant stimulatory effect between the antimicrobial substance and test extract was considered when the combined inhibition zone’s diameter enlarged by at least 5 mm.
3 Results and Discussion
3.1 Analytical aspects of Arctii folium extracts
Chemical qualitative aspects and the polyphenols content, of Arctium lappa whole and selective leaf extracts have been established by using an (HP)TLC method. Studies (Figure 1 – chromatograms A1, A2 and A3) indicated the three polar extracts (the whole ethanol extract/W, ethyl acetate fraction/EA and aqueous fraction/AQ) as containing two main polyphenol subclasses, the caffeoylquinic acid isomers (blue fluorescent/fl. spots - s2, s3’, s5’ and s6) and quercetin derivates (orange fl. spots - s1, s3, s4 and s5) and the nonpolar, chloroform fraction/CHL, which did not reveal any polyphenol compounds. Based on the literature data , but also on the current reference substances/ref. used (see T4, T5, T6, T7 and T8 tracks), the main spots were attributed to rutin (s1/Rf≈0.43), chlorogenic acid (s2/Rf≈0.52/0.55 – the major compound in the whole ethanol extract/W and subsequent aqueous fraction/AQ), neochlorogenic acid (s3/Rf≈0.61/0.64) hyperoside (s3’/Rf≈0.68/0.64), isoquercitrin (s4/Rf≈0.69/0.71), quercitrin (s5/Rf≈0.77), cynarin (s5’/Rf≈0.77) and another major caffeoylquinic acid isomer (s6/Rf≈0.90/0.92 – the major compound in ethyl acetate fraction/EA) attributed to 1,5-di-O-caffeoyl-4-O-maloylquinic acid .
Furthermore, some differences were revealed between the extracts obtained from leaves collected at different vegetation times; Arctii folium derived products from September (chromatogram A3) did not reveal the presence of quercetin-3-O-rutinoside/rutin and corresponding monoglycoside, quercetin-3-O-rhamnoside/quercitrin, previously seen  in Arctii folium extracts during the June period (chromatograms A1 and A2).
Regarding chemical quantitative aspects, the whole ethanol extract/W, and aqueous/AQ and ethyl acetate/EA selective extracts were made to provide the exact content of 5 mg total phenols (GAE) / mL sample.
Designed so as to ensure identical levels of the non-polar compounds as the whole extract/W, the selective chloroform extract/CHL also indicated small amounts of phenolic compounds (0.125 mg GAE / mL sample), even if not confirmed by TLC studies.
3.2 Evaluation of the minimum inhibitory concentration (MIC)
Defined as the lowest concentration of an antimicrobial agent that, under defined in vitro conditions, prevents the appearance of visible growth of the microorganism after its incubation overnight (CLSI, ISO), minimum inhibitory concentration (MIC) appraisal was carried out using an accurate working scheme (Table 1S) and precisely quantified test vegetal samples as concerning the total phenols content (μg GAE per 1 mL sample).
The results (Table 1) suggest reserved antimicrobial potency of Arctii folium extracts, the best results being shown on S. epidermidis ATCC 12228 (precisely the aqueous fraction/AQ and the whole extract/W), with MIC values measuring 32 and 128 μg GAE / mL sample.
On P. mirabilis ATCC 29245 and S. aureus ATCC 25923 as well as on S. aureus ATCC 6538, the whole extract/W and the aqueous fraction/AQ indicated identical MIC values of 256 μg GAE / mL sample.
The results also reveal the lack of activity of all tested extracts against B. cereus ATCC 11778, E. faecalis ATCC 29212 and the three E. coli ATCC strains, as well as the inefficiency of the nonpolar chloroform fraction (CHL) on all microbial strains studied.
Furthermore, the nine bacterial strains properly developed on MHA and MHA plus (20%, v/v) propylene glycol solution (MHA + PG) medium, thus proving the lack of influence on the bacterial growth (positive control).
3.3 Effects of Arctii folium extracts upon (six) antibiotics
Studies have been done on six antibiotics (Ampicillin/AM, Tetracycline/TE, Ciprofloxacin/CIP, Sulfamethoxazole-Trimethoprim/SXT, Chloramphenicol/C and Gentamicin/CN), each one belonging to a separate class of antibiotic, with the antimicrobial used being classed by the official reports of the European Union as effective , and in the same time being extensively used for treating infections worldwide.
As a working principle, all combinations (antibacterial substance - vegetal extract) were studied on all bacterial strains (Table 2), excepting those combinations and strains for which MIC values could not be precisely determined; these cases were pointed out as ND (not determined).
For each antimicrobial substance (positive control/C), four combinations with the vegetal extracts (C+W, C+AQ, C+EA and C+CHL) were tested, and a significant stimulatory effect between the antimicrobial substance and the test extract was considered when the combined inhibition zone’s diameter enlarged by at least 5 mm .
Therefore, compared to the antibiotic alone (positive control/C), Ampicillin/AM (Figure 2) and Arctii folium extracts showed the best results against E. coli ATCC 11229 and B. cereus ATCC 11778 strains. Ampicillin’s combinations with Arctii folium extracts were also effective on the two S. aureus strains (ATCC 6538 and ATCC 25923) and E. faecalis ATCC 29212, while on S. epidermidis ATCC 12228, P. mirabilis ATCC 29245 and the other two E. coli strains (ATCC 35218 and ATCC 8739), only inhibitory effects or the lack of activity were observed.
Tetracycline/TE (Figure 3) and Arctii folium polar extracts (W, AQ and EA) showed good cooperation in making final antimicrobial activity, on all microbial strains. The most important stimulatory effects were noticed on E. faecalis and the three E. coli strains (EA and AQ), but also on B. cereus, the two S. aureus strains and P. mirabilis.
Ciprofloxacin/CIP (Figure 4) combined with Arctii folium extracts demonstrated stimulatory, but inhibitory, effects too. The most important stimulatory effects were provided by the whole extract (W) in case of B. cereus ATCC 11778 and S. aureus ATCC 25923, while the most important inhibitory effects have been noticed in case of the aqueous fraction/AQ (appraised up to -19% inhibitory effect).
Sulfamethoxazole-Trimethoprim/SXT (Figure 5) combinations (mainly with the whole extract/W) resulted in stimulatory effects upon P. mirabilis ATCC 29245, both S. aureus strains and E. faecalis ATCC 29212, the other microbial strains being practically unreactive to this combination. Similar to CIP combinations, the aqueous fraction/AQ as well as ethyl acetate fraction/EA along with SXT induced numerous inhibitory effects, mainly on S. epidermidis ATCC 12228 (EA lead up to -28% inhibitory effect).
Chloramphenicol/C (Figure 6) gained substantial efficacy after combining with Arctii folium polar and non-polar extracts on all tested bacteria, excepting S. epidermitis ATCC 12228 and E. coli ATCC 8739; the most important synergistic activities were obtained against E. faecalis ATCC 29212 (induced by polar extracts), both S. aureus strains and B. cereus ATCC 11778 (induced by polar and non-polar extracts), as well as upon E. coli ATCC 35218 and E. coli ATCC 11229 (induced by aqueous/AQ and/or ethyl acetate/EA fractions). E. coli ATCC 8739 strain indicated prominent inhibitory effects by combining with AQ and EA fractions (appraised as -40% for both cases).
Gentamicin/CN (Figure 7) along with Arctii folium whole extract/W lead to stimulatory effects, the other vegetal extracts resulting in less augmented stimulatory but inhibitory effects (mainly induced by aqueous/AQ and ethyl acetate/EA fractions) too. The most susceptible bacterial strains to CN combinations with the whole extract/W were E. faecalis 29212, followed by the two S. aureus strains, P. mirabilis ATCC 29245 and B. cereus ATCC 11778; an important inhibitory effect of the aqueous fraction/AQ was recorded against S. aureus 25923 (-21% inhibitions).
In terms of stimulation and/or inhibition percentage improvement compared to the antibiotic alone, the relative ratio (%) computed respectively (see Table 2S), certain increases in susceptibility of the S. aureus ATCC 6538 strain (Figure 1S) by combining TE, C and SXT with Arctii folium extracts was clearly seen, mainly with the whole extract/W and ethyl acetate/EA fraction. Proving these, Tetracycline/ TE combined with W and EA showed the highest capacity to increase the antimicrobial effcacy leading up to 35% and, respectively, 37% stimulatory effects compared to the antibiotic alone (this meaning up to 12% and, respectively, 16% synergistic activity), Chloramphenicol/C led to 35% and 31% stimulatory effects compared to the antibiotic alone therefore appraised as 12% and 10% synergistic activity; Sulfamethoxazole-Trimethoprim/SXT led to 25% and 32% stimulatory effects compared to the antibiotic alone further calculated as 6% and, respectively, 12% synergistic activity.
The S. aureus ATCC 25923 strain (Figure 2S) also indicated increased susceptibility after combining tested antibiotics with the whole extract/W and ethyl acetate/EA fraction, Chloramphenicol/C, Ampicillin/AM, Ciprofloxacin/CIP and Tetracycline/TE combinations indicating the best cooperation in making the final antimicrobial activity (it was measured up to 44% antimicrobial efficacy boost compared to the antibiotic alone meaning up to 20% synergistic activity).
Regarding the S. epidermitis ATCC 12228 strain, most of the studied antimicrobial combinations led to inhibitory effects or no effects; the only exception was that of Tetracycline/TE which showed stimulatory effects when combined with the EA fraction. It must be noticed that Arctii folium polar extracts (AQ and W) indicated a certain antimicrobial activity on S. epidermidis 12228 (MIC values measuring 32 and 128 μg GAE / mL sample), so that the lack of synergistic activity of Arctii folium extracts along with antibiotics tested convey the normal behavior of a synergistic product.
The P. mirabilis ATCC 29245 strain (Figure 3S) proved to be sensitive especially to the whole extract/W combination with SXT (the stimulatory effect was appraised up to 40% compared to the antibiotic alone meaning 17% synergistic activity), but also with CIP (up to 20% stimulatory effect compared to the antibiotic meaning 7% synergistic activity) and CN (up to 28% stimulatory effect compared to the antibiotic meaning 4% synergistic activity) antibiotics.
Studies on the three E. coli strains have indicated several prominent synergistic effects, precisely when combining aqueous/AQ and ethyl acetate/EA fractions with TE, AM or C antibiotics.
Thus, E. coli ATCC 35218 (Figure 4S) has been very sensitive to TE combinations with AQ and EA leading up to 35% and, respectively, 80% antimicrobial efficacy increases compared to the antibiotic alone further estimated as 8% and, respectively, 44% synergistic activities.
E. coli ATCC 11229 (Figure 5S) also reacted to AM combinations with AQ and EA fractions leading up to 110% and 160% antimicrobial efficacy increases compared to the antibiotic alone estimated as 25% and 50% synergistic activities.
E. coli ATCC 11229 has also been sensitive to TE and C combinations with the two polar extracts, AQ and EA, leading to 4 and 42% and, respectively, 17 and 8% synergistic activities. E. coli ATCC 8739 (Figure 6S) reacted to TE combinations with AQ and EA fractions achieving 4% and 11% synergistic activities.
B. cereus ATCC 11778 strain (Figure 7S) has revealed a high susceptibility to AM, TE and CIP combinations with AQ, W and CHL extracts, and less effective with the EA fraction; thus, AM and Arctii folium extracts lead to an antimicrobial efficacy increase of 133% when combined with AQ (meaning 27% synergistic activity) and of 150% when in combination with CHL (36% synergistic activity); TE and Arctii folium extracts lead to an increase in antimicrobial efficacy of 25% when combined with W (12% synergistic activity) and of 40% when combined with AQ (21% synergistic activity); CIP and Arctii folium extracts led to an antimicrobial efficacy increase of 25% when combined with the whole extract/W (9% synergistic activity) and of 50% in combination with the chloroform fraction/CHL (27% synergistic activity).
E. faecalis ATCC 29212 (Figure 8S) showed increased sensitivity after combining TE, C and AM with Arctii folium all polar extracts (W, AQ and EA): TE combinations led to 89%, 67%, and 111% antimicrobial efficacy increases compared to the antibiotic alone meaning 21%, 7%, and 36% synergistic activities; C combinations led up to 42%, 47%, and 47% antimicrobial efficacy boosts and 12%, 17%, and 17% synergistic activities, while AM combinations lead up to 32%, 42%, and 37% antimicrobial efficacy boosts and 4%, 12%, and 8% synergistic activities respectively.
Thus, with 22 synergistic interactions (meaning signifcant biological activity certified by a combined inhibition zone exceeding 5 mm diameter) and only one situation of inhibitory effect, Arctii folium whole (70%, v/v) ethanol extract/W with exactly 5 mg gallic [GAE] acid equivalents per 1 mL sample appear as the most realistic synergistic product along with the six (susceptible) antimicrobials tested, mainly with the Tetracycline/TE antibiotic.
Therefore, based on the present study, three conclusions and potential uses have been drawn: first of all, the unpredictable effect (stimulatory or inhibitory) of Arctii folium derived products (mainly the aqueous extract/AQ) in combination with current antibiotics has been demonstrated; secondly, the results suggest potential uses of Arctii folium whole (70%, v/v) ethanol extract in restoring the activity of the antibiotics affected by microbial resistance; lastly (and also backed up by our previous studies on Epilobi hirsuti herba extracts ), further studies on separate compounds and flavonols (eg., myricetin and quercetin derivates ) combinations with phenylcarboxilic acids (e.g., gallic and caffeic acid derivates) are proposed as a starting point for developing new, natural synergistic agents useful in the antibiotic industry. Found to be present in all of the polar extracts (W, AQ and EA), the two main quercetin monoglycosides, hyperoside (s3) and isoquercitrin (s4) respectively, are the most probable active (synergistic) compounds in Arctii folium derived products. While the quantity and rate of these two quercetin monoglycosides, as well as the copresence of different quantity and quality of phenolic acids could explain the similarities, but also the differences between the three polar vegetal extracts, the microbial susceptibility to antibiotics and vegetal compounds could explain the final reaction of bacteria to each combination studied. Regarding the non-polar, chloroform fraction (CHL), this could be active on the basis of its non-polar status thus allowing a better internalization of the active compounds into bacteria.
Finally, the results may be useful for physicians and pharmacists who are currently using phytomedicines and plant based medicines, in order to avoid potential interactions between Arctii folium derived products and antibiotics.
The authors from National Institute of Chemical Pharmaceutical Research and Development (ICCF) - Bucharest Romania, gratefully acknowledge the financial support from project POC ID P_40_406, SMIS 105542 sustaining the design and development of plant derived products, their chemical characterization and data processing.
Jingvi L., Yi-Zhong C., Ricky N.S.W., Calvin, K.F.L., Sydney C.W.T., Stephen C.W.S., Yao T., Yanbo Z., Comparative Analysis of Caffeoylquinic Acids and Lignans in Roots and Seeds among Various Burdock (Arctium lappa) Genotypes with High Antioxidant Activity, J. Agric. Food Chem., 2012, 60, 4067– 4075. CrossrefPubMedWeb of ScienceGoogle Scholar
Chan Y.S., Cheng L.N., Wu J.H., Chan E., Kwan Y.W., Lee S.M.Y., Leung G.P.H., Yu P.H.F., Chan S.W., A review of the pharmacological effects of Arctium lappa (burdock), Inflammopharmacology, 2011, 19, 245-254. CrossrefPubMedGoogle Scholar
Tousch D., Bidel L.P.R., Cazals G., Ferrare K., Leroy J., Faucanie M., Chevassus H., Tournier M., Lajoix A.D., Azay-Milhau J., Chemical Analysis and Antihyperglycemic Activity of an Original Extract from Burdock Root (Arctium lappa), J. Agric. Food Chem., 2014, 62, 7738–7745. CrossrefPubMedWeb of ScienceGoogle Scholar
Ferracane R., Graziani G., Gallo M., Fogliano V., Ritieni A., Metabolic profile of the bioactive compounds of burdock (Arctium lappa) seeds, roots and leaves, Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 399-404. Web of ScienceCrossrefPubMedGoogle Scholar
Tita I., Mogosanu G.D., Tita M.G., Ethnobotanical inventory of medicinal plants from the south-west of Romania, Farmacia, 2009; 57, 141-156. Google Scholar
Shimizu J., Yamada N., Nakamura K., Takita T., Innami S., Effects of different types of dietary fiber preparations isolated from bamboo shoots, edible burdock, apple and corn on profiles of rats, Journal of Nutritional Science and Vitaminology, 1996, 42, 527-39. CrossrefPubMedGoogle Scholar
Knott A., Reuschlein K., Mielke H., Wensorra U., Mummert C., Koop U., Kausch M., Kolbe L., Peters N., Stäb F., Wenck H., Gallinat S., Natural Arctium lappa fruit extract improves the clinical signs of aging skin, J Cosmet Dermatol., 2008, 7, 281-289. CrossrefPubMedGoogle Scholar
Maghsoumi-Norouzabad L., Alipoor B., Abed R., Eftekhar S.B., Mesgari-Abbasi M., Asghari J.M., Effects of Arctium lappa L. (Burdock) root tea on inflammatory status and oxidative stress in patients with knee osteoarthritis, Int J Rheum Dis., 2016, 19, 255-261. CrossrefWeb of SciencePubMedGoogle Scholar
Pereira J.V., Bergamo D.C., Pereira J.O., Antimicrobial activity of Arctium lappa constituents against microorganisms commonly found in endodontic infections, Braz Dent J., 2005, 16, 192–196. PubMedCrossrefGoogle Scholar
Gentil M., Pereira J.V., Silva Sousa Y.T.C., Pietro R., Sousa Neto M.D., Vansan L.P., Suzelei de Castro F., In vitro evaluation of the antibacterial activity of Arctium lappa as a phytotherapeutic agent used in intracanal dressings, Phytotherapy Research, 2006, 20, 184-186. CrossrefGoogle Scholar
Awale S., Lu J., Kalauni S.K., Kurashima Y., Tezuka Y., Kadota S., Esumi, H. Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation, Cancer Res., 2006, 66, 1751-1757. PubMedCrossrefGoogle Scholar
Liu L., Tang L., Studies on antimutagenicity of Burdock, Acta Academiae Medicine Nanjing, 1997, 4, 343-345. Google Scholar
Matsumoto T., Hosono-Nishiyama K., Yamada H., Antiproliferative and Apoptotic Effects of Butyrolactone Lignans from Arctium lappa on Leukemic, Planta Med., 2006, 72, 276-278. CrossrefPubMedGoogle Scholar
Miyamoto K., Nomura M., Sasakura M., Matsui E., Koshiura R., Murayama T., Furukawa T., Hatano T., Yoshida T., Okuda T., Antitumor-Activity of Oenothein-B, a Unique Macrocyclic Ellagitannin, Jpn. J. Cancer Res.,1993, 84, 99-103. CrossrefPubMedGoogle Scholar
Hayashi K., Narutaki K., Nagaoka Y., Hayashi T., Uesato S., Therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus, Biol Pharm Bull., 2010, 33, 1199-1205. CrossrefPubMedWeb of ScienceGoogle Scholar
Eich E., Pertz H., Kaloga M., Schulz J., Fesen M.R., Mazumder A., Pommier Y., (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase, J Med Chem., 1996, 39, 86–95. CrossrefPubMedGoogle Scholar
Pirvu L., Hlevca C., Nicu I., Bubueanu C., Comparative Analytical, Antioxidant and Antimicrobial Activity Studies on a Series of Vegetal Extracts Prepared from Eight Plant Species Growing in Romania, Journal of Planar Chromatography, 2014, 27, 346-356. CrossrefGoogle Scholar
Pirvu L., Nicorescu I., Hlevca C., Albu B., Nicorescu V., Epilobi Hirsuti Herba Extracts Influence the In Vitro Activity of Usual Antibiotics on Standard Bacteria, Open Chemistry, 2016, 14, 1-11. Google Scholar
Wagner H., Bladt S., Plant Drug Analysis, Second Ed., Springer, Berlin, 1996. Google Scholar
Reikh E., Schibli A., HPTLC for the Analysis of Medicinal Plants, Thieme, N.Y. Stuttgart, 2008. Google Scholar
Romanian Pharmacopoeia, Xth ed., Ed. Medicala, Bucharest, 1993. Google Scholar
Lakis Z., Mihele D., Nicorescu I., Vulturescu V., Udeanu D.I., The antimicrobial activity of Thymus vulgaris and Origanum syriacum essential oils in Staphylococcus aureus, Streptococcus pneumoniae and Candida albicans, Farmacia, 2012, 6, 857-865. Google Scholar
CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - 9th Edition. CLSI document M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute, 2012. Google Scholar
ISO 20776-1/2006. Clinical laboratory testing and in vitro diagnostic test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. International Organization for Standardization, Geneva, Switzerland, 2006. Google Scholar
Noumedem J.A.K., Mihasan M., Kuiate J.R., Stefan M., Cojocaru D., Dzoyem J.P., Kuete V., In vitro antibacterial and antibiotic-potentiation activities of four edible plants against multidrug-resistant gram-negative species, BMC Complementary and Alternative Medicine, 2013, 13, 190-199. CrossrefWeb of SciencePubMedGoogle Scholar
European Food Safety Authority (EFSA) & European Centre for Disease Prevention and Control (ECDC), EU Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2013. EFSA Journal 2015, 13, 4036. Google Scholar
Ahmad I., Aqil F., In vitro efficacy of bioactive extracts of 15 medicinal plants against ESbL producing multidrug-resistant enteric bacteria, Microbiological Research, 2007, 162, 264-275. CrossrefGoogle Scholar
Lin R.D., Chin Y.P., Lee M.H, Antimicrobial activity of antibiotics in combination with natural flavonoids against clinical extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae, Phytother Res, 2005, 19, 612-617. PubMedCrossrefGoogle Scholar
About the article
Published Online: 2017-04-30
Conflict of interest: The authors declare no competing financial interest.